The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for dostarlimab (GlaxoSmithKline Australia Pty Ltd)
Active ingredients
dostarlimab
Date of review outcome
Lapse date
Type
Priority review
Indication
JEMPERLI is indicated in combination with platinum-containing chemotherapy for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite high (MSI-H) endometrial cancer.
Therapeutic area
Oncology